Logo image of INKT

MINK THERAPEUTICS INC (INKT) Stock Fundamental Analysis

USA - NASDAQ:INKT - US6036932019 - Common Stock

14.92 USD
-1.38 (-8.47%)
Last: 9/23/2025, 8:00:02 PM
15.59 USD
+0.67 (+4.49%)
After Hours: 9/23/2025, 8:00:02 PM
Fundamental Rating

0

INKT gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. INKT may be in some trouble as it scores bad on both profitability and health. INKT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INKT had negative earnings in the past year.
INKT had a negative operating cash flow in the past year.
In the past 5 years INKT always reported negative net income.
INKT had a negative operating cash flow in each of the past 5 years.
INKT Yearly Net Income VS EBIT VS OCF VS FCFINKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -453.80%, INKT is doing worse than 95.72% of the companies in the same industry.
Industry RankSector Rank
ROA -453.8%
ROE N/A
ROIC N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INKT Yearly ROA, ROE, ROICINKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

INKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INKT Yearly Profit, Operating, Gross MarginsINKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, INKT has more shares outstanding
The number of shares outstanding for INKT has been increased compared to 5 years ago.
INKT has a worse debt/assets ratio than last year.
INKT Yearly Shares OutstandingINKT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M
INKT Yearly Total Debt VS Total AssetsINKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -103.78, we must say that INKT is in the distress zone and has some risk of bankruptcy.
INKT's Altman-Z score of -103.78 is on the low side compared to the rest of the industry. INKT is outperformed by 96.28% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -103.78
ROIC/WACCN/A
WACCN/A
INKT Yearly LT Debt VS Equity VS FCFINKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 0.15 indicates that INKT may have some problems paying its short term obligations.
INKT has a Current ratio of 0.15. This is amonst the worse of the industry: INKT underperforms 96.28% of its industry peers.
A Quick Ratio of 0.15 indicates that INKT may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.15, INKT is doing worse than 96.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
INKT Yearly Current Assets VS Current LiabilitesINKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.22% over the past year.
EPS 1Y (TTM)41.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

INKT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.72% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.59%
EPS Next 2Y19.76%
EPS Next 3Y10.81%
EPS Next 5Y4.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INKT Yearly Revenue VS EstimatesINKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2028 2029 2030 20M 40M 60M 80M
INKT Yearly EPS VS EstimatesINKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INKT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INKT Price Earnings VS Forward Price EarningsINKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INKT Per share dataINKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.76%
EPS Next 3Y10.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INKT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MINK THERAPEUTICS INC

NASDAQ:INKT (9/23/2025, 8:00:02 PM)

After market: 15.59 +0.67 (+4.49%)

14.92

-1.38 (-8.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners1.58%
Inst Owner Change-13.35%
Ins Owners8.09%
Ins Owner Change0.15%
Market Cap67.44M
Analysts82.5
Price Target39.78 (166.62%)
Short Float %3.16%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-51.3%
Min EPS beat(2)-90.1%
Max EPS beat(2)-12.5%
EPS beat(4)1
Avg EPS beat(4)-21.36%
Min EPS beat(4)-90.1%
Max EPS beat(4)38.73%
EPS beat(8)4
Avg EPS beat(8)-0.91%
EPS beat(12)7
Avg EPS beat(12)3.81%
EPS beat(16)9
Avg EPS beat(16)-3.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)11.43%
EPS NQ rev (1m)4.29%
EPS NQ rev (3m)-90%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.88
EYN/A
EPS(NY)-3.73
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0
BVpS-5.57
TBVpS-5.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -453.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -103.78
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)185.6%
Cap/Depr(5y)359.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.43%
EPS Next Y43.59%
EPS Next 2Y19.76%
EPS Next 3Y10.81%
EPS Next 5Y4.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.56%
OCF growth 3YN/A
OCF growth 5YN/A